guest column

Houston expert shares why prototyping is so important to startups

Making a product that is worth further investing in, one that customers will want to buy, requires several prototypes, sometimes tens of prototypes to prove the concept and perfect your idea. Photo courtesy of OKGlobal

Rarely in life is anything perfect on the first attempt. Writers write drafts that are proofed and edited. Musicians practice over and over, and athletes train for years to perfect their skills before becoming pros. So, it only makes sense that a product developer would develop a prototype before manufacturing their products.

But why? Why can't a perfectly designed product go straight from CAD to production? In reality, making a product that is worth further investing in, one that customers will want to buy, requires several prototypes, sometimes tens of prototypes to prove the concept and perfect your idea. Success comes through practice, just like with the musicians and the athletes.

Defining "prototype"

The word prototype derives from the Greek word meaning, "primitive form." It's an early sample or model of a product built to test a concept or process. Understanding that a prototype, by definition, is an early form of your final product, know that there is often a compromise between your prototype and the final product design. Differences in materials, manufacturing processes and design may create a slightly different look and feel of your prototype.

A full design build is expensive, and it can be time-consuming, so before manufacturing, we create a prototype. This allows you to look for any flaws and problems, figure out solutions, then rebuild with the updates. The process may repeat multiple times. Rapid prototyping is often used for your initial prototype, allowing you to inexpensively build and test the parts of the design that are most likely to be flawed, solving issues on the front end, before you make the full product.

This necessary step is needed to progress with your product development and take you further toward the commercialization and marketing of your product.

Why prototype?

Prototyping allows you to learn about the product, the design, and the functionality. By doing repetitive prototyping, you eliminate the guesswork and base your decisions on actual data and facts. Don't ever guess. Just learn. Just prototype.

Market Testing
It allows you to put a product in front of your consumers, get their opinion, and make changes based on how the consumer uses the prototype.

Save Money
You get to save money on initial product testing, by letting consumers test the product the way they would use it in real life.

Make Improvements
Prototyping gives you the opportunity to make improvements before putting your product into the market. You can see where/if your idea is flawed and flush it out before you manufacture products that won't sell.

Sales Forecasting
This is a difficult enough task as it is, but when you have a new product, it's hard to predict how it will fare against other products in the market. By watching how consumers use the prototype, and by seeing it work against other products, you will begin to understand the sales cycle for that product, allowing you to start your forecasting.

Product designers cannot predict how a consumer will react to a new product, so they release several prototypes, and gather feedback, switching up the products until they find what works for the consumer. When the product went to manufacturing, and finally to market, it was almost guaranteed to be a success—an unintended use for prototyping, and yet one of its best uses.

Designers realize that what looks good on paper isn't always what the end-user is going to want. By getting an inexpensive prototype in front of consumers, designers have been able to get quick feedback, adjust the product, and create a winning product.

When it doubt, prototype it out

The beauty of prototyping is that each prototype interaction opens new opportunities to improve your product. In all reality, you will need more than one prototype to develop a truly valuable product. Product development can get bogged down in meetings, where the product is analyzed, and guesses are made as to "the best way," but by getting to the rapid prototype stage, you can skip some of that guesswork and replace it with real information from the customers.


------

Onega Ulanova is the founder of OKGlobal.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News